Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus Salvadori Nicolas auteur aut IRD Fan B. auteur aut IRD Teeyasoontranon W. auteur aut IRD Ngo-Giang-Huong Nicole auteur aut IRD Cressey Tim auteur aut IRD Decker Luc auteur aut IRD Jourdain Gonzague auteur aut IRD et al. auteur aut IRD text journalArticle eng text/pdf born digital access In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. specialized THAILANDE 050 052 Clinical Infectious Diseases 69 1 144-146 2019 1058-4838 https://www.documentation.ird.fr/hor/fdi:010076467 10.1093/cid/ciy982 1058-4838 [F B010076467] https://www.documentation.ird.fr/hor/fdi:010076467 https://www.documentation.ird.fr/intranet/publi/depot/2019-09-10/010076467.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2019-09-10 2019-11-19 fdi:010076467 fre